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Key Points: 
1. LN-derived CLL cells have increased capacity for T-cell activation and superior immune 
synapse formation compared to those from PB.  
2. Enhanced CLL cell immunological function is also linked to PB circulating cells with the 
propensity to migrate.  
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Abstract  
Several lines of evidence suggest that homing of tumor cells to lymphoid tissue contributes to 
disease progression in chronic lymphocytic leukemia (CLL). Here we demonstrate that lymph 
node (LN)-derived CLL cells possess a distinct phenotype and exhibit enhanced capacity for T-
cell activation and superior immune synapse formation when compared to paired peripheral 
blood samples (PB). LN-derived CLL cells manifest a proliferative, CXCR4dimCD5bright, 
phenotype compared to those in the PB and higher expression of T-cell activation molecules 
including CD80, CD86 and HLA-DR. In addition, LN-CLL cells have higher expression of α4β1 
(CD49d) which, as well as being a co-stimulatory molecule, is required for CLL cells to undergo 
transendothelial migration (TEM) and enter the proliferation centers of the LNs.  
Using an in-vitro system that models circulation and TEM, we showed that the small population 
of CLL cells that migrate are CXCR4dimCD5bright with higher CD49d, CD80, CD86 and HLA-DR 
compared to those that remain circulating; a phenotype strikingly similar to LN-derived CLL 
cells. Furthermore, sorted CD49dhi CLL cells showed enhanced capacity to activate T-cells 
compared to CD49dlo sub-populations from the same patient. Thus, although PB-CLL cells have 
reduced capacity to form immune synapses and activate CD4+ T-cells, this was not the case for 
LN-CLL cells or those with the propensity to undergo TEM.  Taken together, our study suggests 
that CLL cell immunological function is not only modulated by microenvironmental interactions 
but is also a feature of a sub-population of PB-CLL cells that are primed for lymphoid tissue 
homing and interaction with T-cells. 
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Introduction 
Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy that follows a remarkably 
diverse clinical course. It is characterized by an accumulation of mature B-lymphocytes in the 
peripheral blood, bone marrow (BM) and secondary lymphoid organs such as the lymph nodes1. 
Since circulating tumor cells generally have a very low proliferation rate, it was originally 
assumed that CLL was primarily a disease of failed apoptosis. However, in-vivo studies of tumor 
kinetics, using deuterated water, revealed higher than expected tumor cell turnover, with a birth 
rate of up to 2% per day2.  
 
The proliferative component of CLL appears to be confined to pseudofollicles or proliferation 
centers in secondary lymphoid tissues3,4 where interactions with non-neoplastic T-cells5,6, and 
follicular dendritic cells7 take place and promote tumor cell growth4. In contrast, very few CLL 
cells in the peripheral circulation show features of proliferation and those that do are believed to 
represent recent emigrants from the lymph node8. In the peripheral circulation, CLL cells 
transiently interact with endothelial cells, which stimulate survival9, but not proliferation10. These 
findings suggest a two-compartment model of disease in which CLL cells traffic between the 
peripheral vasculature and the lymphoid tissues. In support of this, Herishanu et al. compared 
the gene expression of CLL cells in different compartments and identified the LN as the 
predominant site of CLL cell activation and proliferation11. Since disease progression occurs 
when tumor proliferation outstrips loss, the capacity of tumor cells to migrate into tissues is an 
important factor in determining outcome. Transit of CLL cells to the tissues is mediated, at least 
in part, by their expression of CD49d12 and the chemokine receptors such as CXCR4 and 
CXCR513-15 and is controlled by the secretion of the chemokine ligands including CXCL12 and 
CXCL13.   
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Work by Calissano et al8 used in vivo deuterium incorporation to study the phenotype and gene 
expression of the resting and proliferative fraction. They characterized the two compartments 
using differences in CD5 expression (which is upregulated following B-cell activation) and 
CXCR4 (which is raised in CLL cells with high sIgM and down-regulated following BCR 
engagement16 or binding of CXCL12). They concluded that distinct subsets of CLL cells exist 
within PB-CLL cells including small populations of CXCR4dimCD5bright and CXCR4brightCD5dim 
cells. They hypothesized that the former are proliferative, recent emigrants from the LN and the 
later ‘older’ resting cells attempting to re-enter the LN.   
 
Several types of interaction are thought to occur in the CLL tissue microenvironment. There is 
good evidence that co-stimulatory signals from activated CD4+ T-cells5,17 play an important role 
in promoting tumor growth. Contact with activated autologous CD4+ T-cells is sufficient to 
induce proliferation of CLL cells in-vitro and analysis of tissue samples from CLL patients 
reveals that proliferating leukemic cells frequently contact activated CD4+ T-cells6,18.  
 
The objective of the present study was to reconcile these findings with the extensive previous 
evidence that CLL cells strongly inhibit T-cell activation19-21. Previous studies assessing the T-
cell activation capabilities of CLL cells have used cells derived from the peripheral blood which it 
has been suggested to induce anergy22. However, these cells are known to have different 
properties to those residing within the lymph nodes6,11. Here we used fine needle aspiration to 
perform functional assays and determine whether matched CLL cells from lymph node (LN-CLL) 
and peripheral blood (PB-CLL) had a distinct compartment-specific phenotype and T-cell 
activation function. In addition, we utilized our novel circulation system to study migration23 in 
order to compare LN-derived CLL cells with CLL cells that migrated in-vitro.   
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Materials and Methods 
 
Patient samples 
Matched PB and LN FNA sampling was undertaken simultaneously on 11 patients with a 
diagnosis of CLL and palpable lymphadenopathy. The FNA was performed by the passage of a 
23-gauge needle through the skin once and sampling 6-8 times within the node. PB only was 
taken from another 36 patients. CLL PBMC cells were isolated from whole blood of CLL patients 
by density gradient centrifugation with Lymphoprep (Axis-Shield) or Histopaque (Sigma). All 
were taken with the patients’ informed consent in accordance with the Declaration of Helsinki. 
Normal T and B-cells were derived from healthy volunteers. 
 
Circulation System  
A hollow fibre bioreactor system (FiberCell Systems Inc) was adapted to generate an in-vitro 
model of circulating CLL previously described23 using HUVEC and HMEC endothelial cells (life 
technologies) at 5% CO2 37oC. PB CLL cells were introduced into the circulating system through 
one of the access ports in the circulating compartment and were allowed to circulate for 48 
hours before samples were removed from port D (circulating) and Port C (migrated). CLL cells 
were subsequently immunophenotyped as described below.   
 
Immunophenotyping 
CLL cells recovered from the circulation system, following FNA or PB density gradient 
centrifugation were labeled using the panels shown in supplementary Table 1. For the FNA/PB 
staining a whole blood staining method was performed as per the manufacturer’s instructions 
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and a red cell lysis buffer (eBiosciences). For each antigen the Mean Fluorescent Intensity 
(MFI) of the CD19+/CD5+ CLL cells was recorded.  
 
Mixed lymphocyte reaction (MLR) 
T-cells and B-cells were purified by negative selection (Stem Cell technologies), checked for 
purity by flow cytometry and re-suspended to 106 cells/ml in RPMI complete medium with 1% 
BSA (CM). Enriched (>95%) CLL B-cells from both LN and PB or CD49dhi and CD49dlo (top and 
bottom 20%) were sorted using a BD FACS Aria (gating strategy shown in Supplementary 
Figure 1), re-suspended in CM at 106 cells/ml and for the thymidine-incorporation assay 
irradiated at 30Gy. CLL and T-cells were plated out in triplicate at 1:1 and 1:10 and incubated 
for 48 hours at 5% CO2 37oC then harvested as previously described21. When Natalizumab was 
added, CLL cells were pre-incubated for 20 minutes at 20ug/106 cells before co-culture with T-
cells and a further 20ug/106 cells added every 24 hours. For T-cell flow cytometry (antibody list: 
panels E & F Supplementary Table 1) CD3+CD4+/CD8+ T-cells were tightly gated on and 
expression of HLA-DR, Ki67 and CD69 assessed. For the Ki67 assay, Fix and Perm (Invitrogen) 
was used as per the manufacturer’s instructions except that 0.5µl of 10% NP40 was added per 
50µl of perm buffer. The thymidine incorporation assay was performed as previously 
described21.  
 
Synapse assays 
Quantitative CLL:T-cell synapse assays were performed and analyzed as previously 
described24.  Blinded confocal images were analyzed and CD4+T-cell/APC conjugates were 
identified only when T-cells were in direct contact interaction with CLL APCs (blue fluorescent 
channel). The area analysis tool was then used to measure the total area (μm2) of F-actin (red 
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fluorescent channel) accumulation at all T-cell contact sites and synapses with APCs.  
 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 4.0 and 7.0 (GraphPad Software, 
San Diego, CA). Data was assessed for Gaussian distribution using the D’Agostino-Pearson 
normality test and appropriate tests applied.  
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Results 
 
Comparison of the phenotype of PB and LN CLL cells 
In order to directly compare the phenotype of CLL cells derived from lymph nodes and the 
peripheral circulation, we performed matched FNA and PB sampling on 11 CLL patients with 
lymphadenopathy. Only patients with lymphadenopathy were selected and these patients 
typically have high-risk disease and manifest other markers of poor prognosis (Supplementary 
Table 2). Using multi-color flow cytometry, CD5+/CD19+ CLL cells were gated and MFI of HLA-
DR, CD5, CD80, CD86 and CD69 established. In all cases, LN-CLL cells had significantly 
higher expression of the markers associated with antigen presentation, co-stimulation and 
activation: HLA-DR (p<0.0001), CD5 (p=0.0036), CD80 (p=0.0002), CD86 (p=0.0079) and 
CD69 (p=0.0037; Figure 1A). These findings are in keeping with previous work showing 
activation of CLL cells in the LN11 and support our hypothesis that LN-CLL cells have better T-
cell activation potential than those from the PB. Interestingly, compared to PB-CLL cells, these 
LN-CLL cells also had a phenotype associated with adhesion and migration namely increased 
CD49d (p=0.0021) and CD38 (p=0.0083) and decreased CXCR4 expression (p=0.0003) (Figure 
1B). This may be because BCR activation occurs with in the LN and is associated with 
downregulation of CXCR4. In addition, although raised CXCR4 expression is associated with 
the propensity to migrate, following migration the CLL cells encounter high local concentrations 
of CXCL12 which promotes rapid down regulation of this chemokine receptor. 
Immunosuppressive markers were also analyzed, but expression of PD-L1 and PD-L2 was 
absent in both PB and LN-CLL cells in 5/8 patients and the remaining 3 patients showed very 
low levels with no difference between PB and LN-CLL cells. CD200 expression was high in both 
LN-CLL and PB-CLL (data not shown).  
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Enhanced capacity of LN derived CLL cells to activate T-cells    
Since LN-CLL cells have increased expression of molecules associated with T-cell activation 
compared to their PB counterparts, we next sought to determine whether they also had an 
increased capacity to stimulate normal allogeneic T-cells. Paired LN and PB CLL cells plus 
normal B-cells were mixed with purified CD3+ T-cells from a healthy donor in a MLR and the 
proliferation and activation status of the T-cells was assessed by measuring 3H thymidine 
incorporation and the expression of Ki67, CD69 and HLA-DR by flow cytometry. LN-CLL cells 
induced greater activation of both CD4+ and CD8+ T-cells as measured by their higher 
expression of Ki67, CD69 and HLA-DR when compared with PB-CLL cells and this was 
equivalent to that induced by normal B-cells (Figure 2A and Supplementary Figure 2A). 
Furthermore, enhanced T-cell proliferation was confirmed in the presence of irradiated LN-CLL 
cells, again equivalent to that induced by normal B-cells, as evidenced by significantly increased 
thymidine incorporation (Figure 2A). The CLL cells were purified by negative selection to avoid 
modification of properties by antibody binding; the resultant cells were >95% CD5+CD19+. To 
control for the potential that the small residual non-CLL cell pool contained different numbers of 
APCs, we evaluated the proportion of CD5-CD19-HLA-DR+ cells in the LN and the PB residual 
populations and showed there was no difference: LN 1.4% ±1.2% and the PB 1.9% ±1.8 
(p=0.52; data not shown).  
 
We also compared the ability of normal PB-B-cells, LN-CLL cells and matched PB-CLL cells to 
form immune synapses with autologous CD4+T-cells. Previous work has shown that PB-CLL 
cells exhibit impaired T-cell synapse formation20. Here, we measured synapse assembly 
(CLL:CD4+T-cell conjugates) in four patient samples and demonstrated for the first time that LN-
CLL cells showed enhanced autologous T-cell synapse formation, equivalent to that induced by 
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healthy B-cells24 , when compared to their matched PB-CLL cells (patient 1-4 = p < 0.0001, p = 
0.03, p = 0.05 and p< 0.0001 respectively; Figures 2B-D).  
 
PB-CLL cells that migrate in our in-vitro model possess a strikingly similar phenotype to 
LN-CLL cells 
We investigated whether the phenotype manifested by LN-CLL cells was dependent on their 
residence in the LN microenvironment or could be identified in a subset of PB-CLL cells with a 
propensity to migrate. We used a physiologically relevant in-vitro circulation system of CLL 
(Figure 3A23) into which PBMC from 36 CLL patients were then individually introduced for 48 
hours before samples were harvested. Matched samples were obtained from port D (CLL cells 
remaining in circulation) and port C (those that had migrated through the endothelial cell coated 
fibers into the extravascular space (EVS)).  In keeping with our previous report23, a small 
percentage of CLL cells migrated into the EVS after 48h (1.37% ± 2.32%). Compared to CLL 
cells remaining in the circulating compartment, migrated cells showed lower expression of 
CXCR4 (p=0.0058) as well as increased expression of CD49d (p<0.0002), CD38 (p<0.0001), 
HLA-DR (p=0.0002), CD5 (p=0.0044), CD80 (p<0.0001), CD86 (p=0.0006) and CD69 
(p=0.0007; Figure 3B). This phenotype was strikingly similar to that of LN-derived CLL cells. It is 
worthy of note that when we repeated these experiments without endothelial cells lining the 
hollow fibers there was significantly reduced migration but the tiny number that migrated 
manifested higher levels of CXCR4 (p=0.055; Figure 3C) and no difference in CD5. The other 
phenotypic markers showed similar increases in the absence of endothelial cells (data not 
shown).  These results confirm our previous observation that PB-CLL cells with high CXCR4 
and CD49d have an increased propensity to migrate25, but implies that following 
transendothelial migration, the CXCR4 expression is reduced and CD5 is increased.  
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Migrated and LN-derived CLL cells are CXCR4dim CD5bright compared with their circulating 
and PB-derived counterparts 
The work by Calissano et al8 identified small intra-clonal sub-populations of CLL cells with 
different proliferative characteristics. A small number of CXCR4dim CD5bright CLL cells were 
identified as being the proliferative sub-population and it was hypothesized that these had 
recently emigrated from the LN. Here we demonstrate that the small number of CLL cells that 
have migrated our in-vitro model were enriched for a CXCR4dim CD5bright phenotype when 
compared to those that remained circulating. In addition, we showed a clear negative correlation 
between the expression of CD5 and CXCR4; (p=0.0095; Figure 4A and 4C). Whether these 
cells are recent emigrants from the LN that are better primed to migrate in this system due to 
their enhanced activation status, or whether they are a small population with an increased 
migratory potential remains unknown. However, we repeated this analysis on LN-CLL cells and 
clearly showed that, compared with matched PB-CLL cells, LN-CLL cells also had this 
CXCR4dim CD5bright phenotype (p=0.0051; Figure 4B and 4D). 
  
CD49d expression is associated with expression of activation and costimulatory 
molecules and an increased capacity to activate T-cells  
The phenotype of migrated CLL cells suggests that as well as having a greater propensity to 
migrate their increased expression of co-stimulatory molecules could potentially have a greater 
affect on T-cell activation. It has been previously shown that CD49d expression identifies CLL 
cells that have an increased capacity to undergo transendothelial migration12,23 and interestingly 
it is also a co-stimulatory molecule26. In order to investigate whether there is a link between 
migration and co-stimulation in CLL, we correlated the expression of CD49d with a variety of 
activation and costimulatory molecules in the LN and PB of patients with CLL and in the 
circulating and extravascular compartment of the in-vitro circulation system. We found that 
CD49d expression positively correlated with CD5 expression in both the circulating and EVS 
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compartments of the in-vitro system and in the matched LN/PB ex-vivo samples (p=0.016 and 
p=0.0252 respectively; Figure 4E). There was also a strong and statistically significant 
correlation between CD49d levels and CD80, CD86, HLA-DR, CD69 and CD38 in both in-vitro 
and in-vivo systems (Figure 5) and once again the correlation patterns from the circulating 
model system and the matched LN-CLL and PB-CLL cells are strikingly similar.  
 
Functional assays were not possible with cells harvested from the EVS due to the limited 
number of cells that could be obtained. We instead exploited the observation that CD49dhi CLL 
cells that have the highest migratory potential. We sorted the top and bottom 20% CD49d-
expressing CLL cells (based on MFI) from the PB of 5 CLL patients and compared their ability to 
activate alloreactive T-cells in an MLR.  CD49dhi and CD49dlo CLL cells were mixed with purified 
CD3+ T-cells from a healthy donor and the proliferation and activation status of the T-cells 
assessed by measuring their expression of Ki67, CD69, HLA-DR by flow cytometry and 
incorporation of 3H thymidine as described previously. CD49dhi CLL cells induced greater 
activation of CD4+ and CD8+ T-cells as evidenced by higher expression of Ki67 (p=0.05 and p 
<0.001), CD69 (p=0.05 and p=0.04) and HLA-DR (p=0.03 and p=0.006) when compared to T-
cells co-cultured with CD49dlo CLL cells (Figure 6A and Supplementary Figure 2B). 
Furthermore, enhanced T-cell proliferation was confirmed in the presence of irradiated CD49dhi 
cells by significantly increased thymidine incorporation (p=0.013; Figure 6A). These results 
show that, for CLL cells, there is a clear relationship between the propensity to migrate and the 
ability to activate T-cells.  We have previously demonstrated that blocking CD49d using 
Natalizumab prevented CLL migration in our circulating system23. Here, we investigated whether 
Natalizumab could also inhibit the ability of CLL cells to activate allo-reactive T-cells in an MLR. 
CLL cells from 6 CD49dhi CLL patients were pre-incubated with Natalizumab prior to irradiation 
and co-culture with purified CD3+ T-cells from a healthy donor. Following a 5-day MLR there 
was no difference in the thymidine incorporation of the T-cells incubated with CLL cells in the 
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presence or absence of Natalizumab. This suggests that the functional role of CD49d on these 
cells relates to migratory potential rather than T-cell activation.   
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Discussion 
In this study we set out to compare the phenotypic and functional properties of PB CLL cells 
with those that have undergone transendothelial migration into LNs. Traditionally, investigations 
into the pathophysiology of CLL were largely restricted to peripheral blood-derived cells, but 
recent data demonstrating the key role of the lymph node microenvironment in this disease has 
highlighted the importance of understanding the differences in cells residing within the lymph 
nodes compared to those in the peripheral blood.  
 
In this study we utilized fine needle aspiration to access simultaneous lymph node and 
peripheral blood CLL cells and used this material to answer some important questions regarding 
differences in phenotype and function between the two compartments. Unfortunately no 
matched BM samples were available for this study but previous work by Herishanu et al11 
suggests that this microenvironment is not as pro-proliferative or activation-inducing as the LN. 
Previous comparisons have used disaggregated LN biopsies from cases when there is 
diagnostic doubt or atypical disease behavior. Our study recruited typical cases of CLL and the 
LN sample was fresh suspension cells. Using these samples we clearly demonstrated that LN-
CLL cells had enhanced expression of markers that would induce T-cell activation. In contrast to 
previous studies which suggest that PB-CLL cells are poor APCs22,27, induce T-cell anergy and 
inhibit T-cell activation20,21,28, we showed that LN-CLL cells can induce T-cell activation and 
proliferation. We also showed that, in contrast to PB CLL cells, those from the LN were capable 
of forming immune synapses with autologous CD4+T-cells that were comparable to those 
formed by healthy B and T-cells.  These results provide a plausible explanation for the 
observation that CLL lymph nodes contain significant numbers of activated T-cells, despite the 
known inhibitory effects of the tumor21. It has been suggested that CLL cells might present 
antigen to T-cells29 and thereby initiate a self-sustaining stimulatory loop in which CLL cells 
cause T-cell activation which in turn leads to activation and proliferation of the tumor. The 
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observation that CLL cells are capable of presenting red cell-derived rhesus antigen, causing 
the expansion of auto-reactive T-cell clones in patients with autoimmune hemolytic anemia30, 
provides further in-vivo evidence in support of this theory. Whether the interactions promote an 
anti-tumor response or a self-stimulatory tumor survival loop remains unknown, but the nature of 
the disease suggests it is the latter.  
 
In addition, LN-CLL cells also expressed higher levels of CD49d and CD38, which are both 
involved in transendothelial migration. This suggests there is a link between the enhanced 
ability to activate T-cells and the capacity to migrate. Tissue invasion of CLL requires 
transendothelial migration (TEM) of the malignant cells but a full understanding of the 
mechanisms behind this is not yet available. However, it has been established that CLL clones 
differ from normal B-cells in that they require α4β1 (CD49d) engagement to undergo TEM and 
enter the proliferation centers of lymph nodes12. In addition, CD38  is associated with CD49d31,32 
and homing from the blood to the lymphoid organs33.  In this study we showed that both of these 
poor prognostic markers were expressed at higher levels in LN-CLL cells.  In much the same 
way that we now know that CD38 expression is temporal6,34, it seems likely that CD49d, CXCR4 
and CD5 are also temporally regulated and this could give rise to intra-clonal subsets with a 
higher and lower predisposition to migrate depending on their phenotype. In support of this 
theory, we demonstrated that CD38hi/CD49dhi LN-CLL cells were CXCR4dim CD5bright compared 
to PB-CLL cells which supports the Calissano model of them being the proliferative ‘robust’ 
fraction8.  
 
In order to investigate whether these cells could be identified as a subset in PB-CLL and, if so, 
whether they have an increased propensity to migrate, we utilized our novel in-vitro circulation 
system. We demonstrated that compared to the majority of cells that remained circulating, the 
small population of CLL cells that migrated had significantly higher expression of CD38, CD49d, 
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HLA-DR, CD80, and CD86. In addition, following migration through endothelium, they also 
possessed a CXCR4dim CD5bright phenotype. Importantly, this CXCR4dim CD5bright  phenotype was 
not seen in CLL cells that migrated in the absence of endothelial cells. We therefore 
hypothesized that CXCR4 and CD5 are modulated, at least in part, by endothelial cell contact, 
their secretion of CXCL12 and the process of transendothelial migration. Although the data 
presented here does not completely validate the Calissano model, it does support the concept 
that there is a small and distinct population of CLL cells with a propensity to migrate in the 
peripheral circulation and these cells could well be the recent LN emigrants (Supplementary 
Figure 3).  
 
Importantly, we demonstrated a strong positive correlation between the expression of CD49d 
and that of CD5, HLA-DR, CD80 and CD86 further supporting a link between migration and the 
potential for increased contact with, and activation of, T-cells. These correlations were 
confirmed in matched LN-CLL and PB-CLL cells adding weight to the argument that these 
phenotypes are physiologically relevant. 
 
The limited numbers of cells that migrated in our in-vitro model prevented functional assays 
from being performed but, as it is CLL cells with the highest expression of CD49d that migrate, 
we compared the T-cell stimulatory properties of CD49dhi with CD49dlo CLL cells derived from 
the same patient. These assays demonstrated that CD49dhi CLL cells induce superior T-cell 
activation. We have previously shown that blocking CD49d with Natalizumab prevents CLL cell 
migration but, interestingly, here we have established that CD49d itself is not directly 
responsible for T-cell activation. This supports the hypothesis that the poor prognosis 
associated with CD49d expression in CLL is predominately caused by its ability to modulate 
tumor cell migration rather than directly induce T-cell activation.  
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CLL is a disease characterized by immune suppression that is exemplified by poor responses to 
vaccination. However, a number of studies have shown that this suppression is not 
irreversible,35,36 PD-1 is not always a marker of terminal exhaustion and immune responses can 
be reinvigorated by antibody blockade37. Previous contradictory literature indicated that T-cell 
activation in CLL is in equilibrium between pro- and anti-activation signals but here we show that 
there appears to be a balance shift towards pro-activation in the LNs. In support of this, 
Herishanu et al11 demonstrated that LN-CLL cells had the signature of BCR activation and 
Buhman et al27 showed that CD40L expression by CLL cells up regulated T-cell stimulatory 
activity.  
 
Our results add to this by suggesting a role for transendothelial migration in the T-cell activation 
capabilities of the LN-CLL cells. Previously, we have shown that the interaction of CLL cells with 
endothelium in static culture activated NF-κB resulting in enhanced transcription and protein 
expression of NF-κB-regulated genes such as CD38 and CD49d9. In our novel circulation 
system, which more closely simulates the situation in-vivo, a much larger effect was seen in 
migrated cells and as CD49d is also a co-stimulatory molecule26, this further supports the link 
between migration and T-cell activation by CLL cells.         
 
In conclusion, LN-CLL cells manifest a distinct phenotype to those in the PB and demonstrate 
an enhanced capacity for T-cell activation and immunological synapse formation. Data from our 
in-vitro circulation model implies that there is a link between the process of migration and these 
phenotypic and functional differences. Clearly the microenvironment plays a vital role in the 
pathology of CLL but it would appear that, within a patient, a subset of CLL cells with a distinct 
phenotype are inherently more capable of migrating and are primed for interaction with T-cells. 
Although the striking reduction in tumor bulk observed with drugs like Ibrutinib and Idelalisib is 
only partially due to tissue redistribution38,39, it seems likely that their clinical effect is, at least in 
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part, elicited by inhibiting CLL cell lymphoid tissue homing, which consequently prevents antigen 
presentation, T-cell activation and tumor proliferation. 
 
 
Acknowledgements 
This work was funded in part by Bloodwise (MP, EW & KC) Kay Kendall Leukaemia Fund (EC) 
and British Society of Haematology (BA).    
 
Authorship Contributions 
A.G.S.B. designed the research, performed experiments and co-wrote the paper, M.P., E.W, 
DY, E.C, B.A, K.C. P.P, E.P. and M.S.L. performed practical work, L.B., C.D.F and A.G.R 
provided analytical tools and C.P and S.D. designed research and co-wrote the paper.  
 
Conflicts-of-interest disclosure 
The authors declare no competing financial interests. 
For personal use only.on June 2, 2016. by guest  www.bloodjournal.orgFrom 
PASIKOWSKA et al.   FUNCTIONAL DIFFERENCES OF LN VERSUS PB CLL CELLS. 
 
19 
 
 References 
1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 
2005;352(8):804-815. 
2. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic 
cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115(3):755-764. 
3. Swerdlow SH, Murray LJ, Habeshaw JA, Stansfeld AG. Lymphocytic lymphoma/B-
chronic lymphocytic leukaemia--an immunohistopathological study of peripheral B lymphocyte 
neoplasia. Br J Cancer. 1984;50(5):587-599. 
4. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br 
J Haematol. 2003;123(3):380-388. 
5. Ghia P, Strola G, Granziero L, et al. Chronic lymphocytic leukemia B cells are endowed 
with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol. 
2002;32(5):1403-1413. 
6. Patten PE, Buggins AG, Richards J, et al. CD38 expression in chronic lymphocytic 
leukemia is regulated by the tumor microenvironment. Blood. 2008;111(10):5173-5181. 
7. Schmid C, Isaacson PG. Proliferation centres in B-cell malignant lymphoma, 
lymphocytic (B-CLL): an immunophenotypic study. Histopathology. 1994;24(5):445-451. 
8. Calissano C, Damle RN, Marsilio S, et al. Intraclonal complexity in chronic lymphocytic 
leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 
2011;17(11-12):1374-1382. 
9. Buggins AG, Pepper C, Patten PE, et al. Interaction with vascular endothelium enhances 
survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo 
gene transcription. Cancer Res. 2010;70(19):7523-7533. 
10. Hamilton E, Pearce L, Morgan L, et al. Mimicking the tumour microenvironment: three 
different co-culture systems induce a similar phenotype but distinct proliferative signals in 
primary chronic lymphocytic leukaemia cells. Br J Haematol. 2012;158(5):589-599. 
11. Herishanu Y, Perez-Galan P, Liu D, et al. The lymph node microenvironment promotes 
B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic 
leukemia. Blood. 2011;117(2):563-574. 
12. Till KJ, Spiller DG, Harris RJ, Chen H, Zuzel M, Cawley JC. CLL, but not normal, B 
cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility 
on and through endothelium. Blood. 2005;105(12):4813-4819. 
13. Burger JA, Kipps TJ. Chemokine receptors and stromal cells in the homing and 
homeostasis of chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2002;43(3):461-466. 
14. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express 
functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone 
marrow stromal cells. Blood. 1999;94(11):3658-3667. 
For personal use only.on June 2, 2016. by guest  www.bloodjournal.orgFrom 
PASIKOWSKA et al.   FUNCTIONAL DIFFERENCES OF LN VERSUS PB CLL CELLS. 
 
20 
 
15. Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA. 
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic 
lymphocytic leukemia. Blood. 2007;110(9):3316-3325. 
16. Coelho V, Krysov S, Steele A, et al. Identification in CLL of circulating intraclonal 
subgroups with varying B-cell receptor expression and function. Blood. 2013;122(15):2664-
2672. 
17. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and 
interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood. 
2001;97(9):2777-2783. 
18. Patten P, Devereux S, Buggins A, Bonyhadi M, Frohlich M, Berenson RJ. Effect of 
CD3/CD28 bead-activated and expanded T cells on leukemic B cells in chronic lymphocytic 
leukemia. J Immunol. 2005;174(11):6562-6563; author reply 6563. 
19. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic 
lymphocytic leukemia. Nat Med. 1997;3(9):984-989. 
20. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show 
impaired immunological synapse formation that can be reversed with an immunomodulating 
drug. J Clin Invest. 2008;118(7):2427-2437. 
21. Buggins AG, Patten PE, Richards J, Thomas NS, Mufti GJ, Devereux S. Tumor-derived 
IL-6 may contribute to the immunological defect in CLL. Leukemia. 2008;22(5):1084-1087. 
22. Ranheim EA, Cantwell MJ, Kipps TJ. Expression of CD27 and its ligand, CD70, on 
chronic lymphocytic leukemia B cells. Blood. 1995;85(12):3556-3565. 
23. Walsby E, Buggins A, Devereux S, et al. Development and characterization of a 
physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. 
Blood. 2014;123(23):3607-3617. 
24. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired 
T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with 
lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 
2012;120(7):1412-1421. 
25. Pepper C, Buggins AG, Jones CH, et al. Phenotypic heterogeneity in IGHV-mutated CLL 
patients has prognostic impact and identifies a subset with increased sensitivity to BTK and 
PI3Kdelta inhibition. Leukemia. 2015;29(3):744-747. 
26. Udagawa T, Woodside DG, McIntyre BW. Alpha 4 beta 1 (CD49d/CD29) integrin 
costimulation of human T cells enhances transcription factor and cytokine induction in the 
absence of altered sensitivity to anti-CD3 stimulation. J Immunol. 1996;157(5):1965-1972. 
27. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-cell 
chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus 
autologous T cells generates different types of effector cells. Blood. 1999;93(6):1992-2002. 
28. Grant AM, Wileman SM, Ramsay CR, et al. Minimal access surgery compared with 
medical management for chronic gastro-oesophageal reflux disease: UK collaborative 
randomised trial. BMJ. 2008;337:a2664. 
For personal use only.on June 2, 2016. by guest  www.bloodjournal.orgFrom 
PASIKOWSKA et al.   FUNCTIONAL DIFFERENCES OF LN VERSUS PB CLL CELLS. 
 
21 
 
29. Os A, Burgler S, Ribes AP, et al. Chronic lymphocytic leukemia cells are activated and 
proliferate in response to specific T helper cells. Cell Rep. 2013;4(3):566-577. 
30. Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T 
cells in chronic lymphocytic leukemia by malignant B cells. Blood. 2005;105(5):2007-2015. 
31. Majid A, Lin TT, Best G, et al. CD49d is an independent prognostic marker that is 
associated with CXCR4 expression in CLL. Leuk Res. 2011;35(6):750-756. 
32. Buggins AG, Levi A, Gohil S, et al. Evidence for a macromolecular complex in poor 
prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol. 
2011;154(2):216-222. 
33. Vaisitti T, Aydin S, Rossi D, et al. CD38 increases CXCL12-mediated signals and 
homing of chronic lymphocytic leukemia cells. Leukemia. 2010;24(5):958-969. 
34. Damle RN, Temburni S, Calissano C, et al. CD38 expression labels an activated subset 
within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood. 
2007;110(9):3352-3359. 
35. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of 
T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612-1621. 
36. Shanafelt TD, Ramsay AG, Zent CS, et al. Long-term repair of T-cell synapse activity in 
a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously 
untreated chronic lymphocytic leukemia (CLL). Blood. 2013;121(20):4137-4141. 
37. McClanahan F, Riches JC, Miller S, et al. Mechanisms of PD-L1/PD-1-mediated CD8 T-
cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse 
model. Blood. 2015;126(2):212-221. 
38. Wodarz D, Garg N, Komarova NL, et al. Kinetics of CLL cells in tissues and blood 
during therapy with the BTK inhibitor ibrutinib. Blood. 2014;123(26):4132-4135. 
39. Fiorcari S, Brown WS, McIntyre BW, et al. The PI3-kinase delta inhibitor idelalisib (GS-
1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to 
endothelial and marrow stromal cells. PLoS One. 2013;8(12):e83830. 
 
  
For personal use only.on June 2, 2016. by guest  www.bloodjournal.orgFrom 
PASIKOWSKA et al.   FUNCTIONAL DIFFERENCES OF LN VERSUS PB CLL CELLS. 
 
22 
 
Figure 1.  LN-derived CLL cells have a phenotype associated with T-cell activation 
and migration.   
Matched LN and PB samples from 11 CLL patients were analyzed using multi-
color flow cytometry and the % change between the LN and PB MFI calculated.  
A. Compared to PB-derived CLL cells, LN-derived CD19+CD5+ CLL cells 
showed higher expression of the markers associated with antigen-
presentation, co-stimulation and activation: HLA-DR, CD5, CD80, CD86 
and CD69.  
B. In addition, they have a phenotype associated with recent migration: 
raised CD49d and CD38 and reduced CXCR4.  
 
 
Figure 2. LN-CLL cells are functionally better at T-cell activation and induce superior 
CLL:T-cell synapses.  
A. Paired LN and PB-CLL cells (irradiated for thymidine-incorporation 
assays) from 6 patients and B-cells from 5 normal donors were mixed at a 
1:1 or 1:10 ratio with allogeneic T-cells in triplicate. Compared to PB-CLL 
cells, LN-CLL cells and normal B-cells have an increased ability to 
stimulate T-cell activation and proliferation, as shown by increased 
expression of Ki67 on gated CD4+ cells and CD8+ cells after a 48 hour co-
culture and increased thymidine-incorporation by CD3+ T-cells in a 5 day 
MLR.  
B. To investigate the ability of the LN-derived CLL cells to induce autologous 
T-cell synapse formation compared to PB-CLL cells and normal B-cells, 
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we measured the area of F-actin polymerization in 90 CLL or B-
cell:CD4+T-cell conjugates in four paired patient samples and one paired 
normal sample. This representative figure from one patient shows the 
increased synapse formation induced by the LN-derived CLL cells 
compared to matched PB-CLL cells. 
C.  Representative result from one patient showing that synapse area was 
significantly greater when LN-derived CLL cells were used (mean 
synapse area induced by LN-CLL 6.534μm2 ±2.7 vs PB-CLL 3.594μm2 
±2.3 p<0.0001).    
D. Representative result from another patient demonstrating the synapse 
area generated by LN-CLL cells is comparable to that of normal B-cells. 
 
Figure 3. CLL cells that migrate have a strikingly similar phenotype to those derived 
from the LN. 
A.  CLL PBMC were introduced in to the circulating model system coated 
with human endothelial cells (HUVEC23 or HMEC-19,10) and samples were 
collected from port C (migrated) and port D (circulating) after 48 hours. 
Matched CD5+/CD19+ CLL cells from each compartment were analyzed 
using multi-color flow cytometry.  
B. Compared to CLL cells that remained circulating, migrated CLL cells had 
a phenotypic pattern strikingly similar to LN-CLL cells: higher HLA-DR 
(n=7), CD5 (n=12), CD80 (n=19), CD86 (n=7), CD69 (n=26), CD49d 
(n=36), CD38 (n=32) and reduced CXCR4 (n=34). CLL cells that 
remained circulating had a pattern reflective of PB-CLL cells. 
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C. PBMCs from 11 patients were introduced into the circulating model 
system in the absence of endothelial cell coating. The numbers of CLL 
cells migrating was much lower than in the presence of endothelial cells 
and only sufficient for analysis migrated from 8 patients.  In these 8 
cases, the migrated CLL cells had increased CXCR4 expression 
compared to those that remained circulating. 
 
Figure 4. Both models show negative correlation between CD5 and CXCR4 but a 
positive correlation between CD5 and CD49d. 
A. A representative figure showing matched circulating and migrated 
CD19+CD5+ CLL cells from a single patient harvested after 48 hours in 
the circulation system. Compared to each other, the migrated CLL cells 
are CD5brightCXCR4dim and the circulating cells CD5dimCXCR4bright. 
B. A representative figure showing matched PB and LN CD19+CD5+ CLL 
cells from a single patient. The LN CLL cells are CD5brightCXCR4dim and 
the PB cells CD5dimCXCR4bright. 
C. For both the migrated and circulating CD19+CD5+ CLL cells, the MFI of 
the CD5 and CXCR4 were established and show a negative correlation. 
This was done on 8 patients and a color assigned to each patient. For 
each case the dots surrounded by a colored box is the result for the 
migrated and that surrounded by an oval in the same color the matched 
circulating result. In each case the migrated cells have higher CD5 and 
lower CXCR4 than the circulating ones.   
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D. The same was done for the LN and PB CD19+CD5+ CLL cells from 11 
patients.  In each case the LN-derived CLL cells have higher CD5 and 
lower CXCR4 (box) than those from the PB (oval). 
E. In both the circulating/migrated model and the LN/PB model CD5 and 
CD49d positively correlate.  
 
Figure 5. Both models show strikingly similar positive correlation between CD49d 
and markers associated with antigen presentation and activation. 
A.  PBMCs were introduced into the circulating model system for 48 hours 
and the MFI values for both the migrated and circulating CLL cells 
recorded. There is a positive correlation between expression of CD49d 
and CD80, CD86, HLA-DR, CD69 and CD38. 
B. MFI data from matched LN and PB CLL cells from 11 patients were 
analyzed for correlation. There is a positive correlation between 
expression of CD49d and CD80, CD86, HLA-DR, CD69 and CD38. 
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Figure 6. CD49dhi CLL cells are superior stimulators of T-cell activation.  
Paired CD49dhi and CD49dlo CLL cells (irradiated for thymidine-incorporation 
assays) from 5 patients were mixed at a 1:1 or 1:10 ratio with allogeneic T-cells 
in triplicate. 
A. Compared to CD49dlo cells, CD49dhi cells have an increased ability to 
stimulate T-cell activation and proliferation as shown by increased expression 
of Ki67 on gated CD4+ and CD8+ cells after 48 hours and increased 
thymidine-incorporation in a 5 day MLR.  
B. Irradiated CLL cells from 6 patients known to express CD49d were mixed at a 
1:1 ratio with allogeneic T-cells in triplicate and in the absence or presence of 
Natalizumab and proliferation measured by thymidine-incorporation in a 5 day 
MLR. Blocking of CD49d had no effect on the ability of CLL cells to induce T-
cell proliferation.  
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